Breakthrough Study Suggests Possible Reversal of Alzheimer’s Disease

Scientists at University Hospitals Cleveland Medical Center have identified a potential method to reverse Alzheimer’s disease in a groundbreaking animal study. The research shows that restoring levels of a crucial cellular energy molecule in mice brains successfully reversed markers of the disease, including brain changes and cognitive decline.

The research team analyzed two different Alzheimer’s mouse models and human Alzheimer’s brain tissue, discovering severe declines in NAD+, an enzyme essential for energy production, cell maintenance, and long-term cellular health that naturally diminishes with age.

“When NAD+ falls below necessary levels, cells cannot effectively perform essential maintenance and survival functions,” explained Dr. Andrew A. Pieper, senior study author and director of the Brain Health Medicines Center at Harrington Discovery Institute at University Hospitals in Cleveland.

Dr. Charles Brenner, chief scientific advisor for Niagen, a company specializing in NAD+-boosting products, highlighted the importance of this molecule for brain function. “The brain consumes around 20% of your body’s energy and has high demand for NAD+ for cellular energy production and DNA repair,” said Brenner, who was not involved in the study. “NAD+ plays a key role in the way that neurons adapt to a range of physiological stressors and support processes associated with brain health.”

In their experiment, the researchers used a medication called P7C3-A20 to restore normal NAD+ levels in mice models. The results were remarkable: the treatment blocked the onset of Alzheimer’s in healthy mice and, more significantly, reversed amyloid and tau build-up in brains with advanced Alzheimer’s while fully restoring cognitive function.

“For more than a century, Alzheimer’s has been considered irreversible,” Dr. Pieper noted. “Our experiments provide a proof of principle that some forms of dementia may not be inevitably permanent.”

The treated mice also showed normalized blood levels of phosphorylated tau 217, an important clinical biomarker used in human Alzheimer’s research. Researchers were particularly impressed by how effectively advanced Alzheimer’s was reversed when NAD+ balance was restored, even without directly targeting amyloid plaques, which have been the focus of many previous treatment approaches.

This research builds upon earlier work from the same lab demonstrating that restoring NAD+ balance accelerated recovery after severe traumatic brain injury. The current study was conducted in collaboration with Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center, with findings published last week in the journal Cell Reports Medicine.

Despite these promising results, significant limitations remain. The researchers emphasize that the study was conducted only in mouse models and may not translate directly to humans. “Alzheimer’s is a complex, multifactorial, uniquely human disease,” Dr. Pieper cautioned. “Efficacy in animal models does not guarantee the same results in human patients.”

The researchers also issued an important warning about over-the-counter NAD+-boosting supplements, which can raise cellular NAD+ to excessively high levels that have been shown to promote cancer in some animal models. “P7C3-A20, by contrast, enables cells to restore and preserve appropriate NAD+ balance under stress without driving NAD+ to excessively high levels,” Dr. Pieper explained. He recommends that anyone considering NAD+-modulating supplements should discuss the risks and benefits with their physician.

While this potential treatment pathway develops, Dr. Pieper highlighted proven lifestyle measures that promote brain resilience, including sufficient sleep, following a MIND or Mediterranean diet, staying cognitively and physically active, maintaining social connections, addressing hearing loss, protecting the head from physical injury, limiting alcohol, controlling blood pressure, and avoiding smoking.

Looking ahead, the research team plans to conduct further studies on the impact of brain energy balance on cognitive health and test whether their strategy might work for other age-related neurodegenerative diseases. This research represents a potentially significant step forward in understanding and eventually treating a disease that affects millions worldwide.